Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
Pfizer presses forward with once-daily GLP-1 pill in long-awaited move
Pfizer is making a move on its obesity pipeline after multiple quarters of questions from investors and analysts.
The New York pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
